本帖最后由 老马 于 2012-1-13 21:20 编辑
! ]$ H, c: \8 T3 X1 g/ O7 M4 a) J4 u O t" d2 l
爱必妥和阿瓦斯丁的比较7 R/ g c4 Z% G1 y; T
2 L3 f$ u: m; G ^$ O$ [+ I( Whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 I4 }) _$ x: L. Y
: @# L6 t' |" Z
7 ~6 {: E+ _: \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
- L* m$ ?) p$ e+ t==================================================
! c1 ]4 ~" {0 {0 c3 eOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: @0 S, G+ f! I! KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& L5 y* C( H6 S5 v. P) r2 ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 g- C( F- ?$ Z
|